Congenital adrenal hyperplasia is one of the most prevalent genetic endocrine diseases. A new guideline from the Endocrine Society offers expert opinion and evidence-based recommendations on the diagnosis and management of this challenging condition.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Mortality in children with classic congenital adrenal hyperplasia and 21-hydroxylase deficiency (CAH) in Germany
BMC Endocrine Disorders Open Access 08 June 2018
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Speiser, P. W. et al. Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: an Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab. 95, 4133–4160 (2010).
Riepe, F. G. & Sippell, W. G. Recent advances in diagnosis, treatment, and outcome of congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Rev. Endocr. Metab. Disord. 8, 349–363 (2007).
Fernández-Balsells, M. M. et al. Prenatal dexamethasone use for the prevention of virilization in pregnancies at risk for classical congenital adrenal hyperplasia due to 21 hydroxylase (CYP21A2) deficiency: A systematic review and meta-analyses. Clin. Endocrinol. (Oxf.) doi: 10.1111/j.1365-2265.2010.03826.x.
Muthusamy, K. et al. Clinical review: Adult height in patients with congenital adrenal hyperplasia: a systematic review and metaanalysis. J. Clin. Endocrinol. Metab. 95, 4161–4172 (2010).
Rivkees, S. A. Dexamethasone therapy of congenital adrenal hyperplasia and the myth of the “growth toxic” glucocorticoid. Int. J. Pediatr. Endocrinol. 2010, 569680 (2010).
Joint LWPES/ESPE CAH Working Group. Consensus statement on 21-hydroxylase deficiency from the Lawson Wilkins Pediatric Endocrine Society and the European Society for Paediatric Endocrinology. J. Clin. Endocrinol. Metab. 87, 4048–4053 (2002).
[No authors listed] Technical report: congenital adrenal hyperplasia. Section on Endocrinology and Committee on Genetics. Pediatrics 106, 1511–1518 (2000).
New, M. I. et al. Prenatal diagnosis for congenital adrenal hyperplasia in 532 pregnancies. J. Clin. Endocrinol. Metab. 86, 5651–5657 (2001).
Arlt, W. et al. Health status of adults with congenital adrenal hyperplasia: a cohort study of 203 patients. J. Clin. Endocrinol. Metab. doi: 10.1210/jc.2010-0917.
Acknowledgements
F. G. Riepe is supported in part by the project EuroDSD in the European Community's Seventh Framework Program FP7/2007-2013 under grant agreement 201444.
Author information
Authors and Affiliations
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Riepe, F. Congenital adrenal hyperplasia: new treatment guidelines. Nat Rev Endocrinol 7, 6–8 (2011). https://doi.org/10.1038/nrendo.2010.197
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrendo.2010.197
This article is cited by
-
Mortality in children with classic congenital adrenal hyperplasia and 21-hydroxylase deficiency (CAH) in Germany
BMC Endocrine Disorders (2018)